News
TolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing
![]()
— Ongoing Phase IIb study expands to arm B
— 5-year results of phase I study confirm efficacy and safety of novel immune-tolerance inducing cell therapy in organ transplantation
— Second closing of Series A round
TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, today announced that in the TOL2- Phase IIb study in renal transplant patients TolerogenixX has received green light by the Safety Board to initiate the B arm of the study. Read more…

